Nogues X, Ovejero D, Pineda-Moncusí M, et al. - Researchers conducted the study for analyzing the impact of calcifediol [25OHD3] treatment on COVID-19-related outcomes. In total, 930 patients with COVID-19 were involved. Ninety-two people were excluded because they had already consumed calcifediol. A total of 447 of the remaining 838 patients received calcifediol (532 ug on day one plus 266 ug on day 3, 7, 15, and 30) whereas 391 were not treated at the time of admission (Intention-to-Treat). According to this observational cohort study, ICU assistance was needed by 102 (12.2%) candidates. Calcifediol treatment significantly reduced ICU admission and mortality in patients hospitalized with COVID-19.